| Course | DNP 955 DPI Project: Part I |
|---|---|
| Topic | Topic 4 |
| Paper type | Evidence arranged by argument |
| Length | About 1,000 words, 3 pages |
| Format | APA 7 student paper |
| School | Grand Canyon University (GCU) |
| Program | DNP |
| Updated | October 2026 |
Free sample paper for DNP 955 Topic 4
Four Claims the Proposal Must Establish, and the One the Literature Cannot Carry: Arranging the Evidence for a Statin Outreach Project by Argument
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
DNP-955: DPI Project: Part I
Topic 4 Assignment
[Instructor Name]
June 25, 2029
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
Four Claims the Proposal Must Establish, and the One the Literature Cannot Carry: Arranging the Evidence for a Statin Outreach Project by Argument
How the Evidence Is Arranged
A literature review in a project proposal is not a demonstration that reading occurred; it is the support for an argument. This proposal has to establish four claims, and the evidence is arranged under them rather than study by study: that the problem matters, that the intervention affects it, that the intervention works in settings resembling this one, and that the chosen measure will detect the change. The project, defined in Topics 1 to 3, has nurse care managers call patients, talk through a statin decision aid with them and, if they choose to start, pend an order for the prescriber to sign; it is aimed at patients in their forties and early fifties whose type 2 diabetes is followed in a composite six-clinic network, where 57 percent currently have a statin ordered or dispensed. Each claim below ends with a statement of how strongly the evidence supports it.
Claim 1: The Problem Matters
The evidence here is strong and direct. A meta-analysis of individual data from 18,686 people with diabetes in 14 randomized statin trials found a 21 percent proportional reduction in major vascular events for each 1 mmol/L reduction in LDL cholesterol, with reductions in myocardial infarction or coronary death, coronary revascularization and stroke, and a benefit similar to that in people without diabetes (Cholesterol Treatment Trialists' Collaborators, 2008). On that basis, the national diabetes standards call for a statin of moderate intensity or more, alongside lifestyle therapy, for people with diabetes between 40 and 75, with no separate risk calculation needed (American Diabetes Association Professional Practice Committee, 2025). For the 418 patients in the project population without a statin, the benefit is not speculative. Strength: strong.
Claim 2: The Intervention Affects the Problem
The evidence here is moderate and partly indirect. The most relevant trial randomized primary care practices at a large academic health system to nudges aimed at clinicians, at patients, at both or at neither, for patients who were eligible for a statin and not taking one. Relative to usual care, the clinician nudge increased statin prescribing by 5.5 percentage points and the combined nudge by 7.2 points, while patient nudges alone did not produce a significant increase (Adusumalli et al., 2023). That matters for this design, because it suggests reaching patients without involving prescribers may not be enough, which supports the protocol-pended order that puts a decision in front of the prescriber. The decision aid, tested in a randomized trial among adults with type 2 diabetes seen in specialty consultations, improved knowledge, risk perception and decisional conflict compared with a standard pamphlet (Weymiller et al., 2007); it was not designed to increase prescribing, and the proposal should not claim it will. Strength: moderate for the prescribing component, and for the decision aid, strong on decision quality but not on uptake.
Claim 3: It Works in Settings Resembling This One
This is where the argument fails, and the proposal must say so. The supporting studies come from settings with resources this network lacks. The nudge trial ran in an academic health system with an informatics team that built patient-specific messages, automated patient texts and a research team to run them (Adusumalli et al., 2023). The decision aid trial ran in specialty diabetes consultations at an academic medical center with endocrinologists who had time to use the aid in the visit (Weymiller et al., 2007). The network in this project has six community clinics, no embedded clinical pharmacists, two nurse care managers who already carry diabetes and hypertension panels, and an informatics analyst shared across all quality work. No study I found tested care manager outreach with a pended order in a small community network with this staffing. Strength: weak.
That result changes the proposal. It adds a feasibility element the design did not previously contain: in the first eight weeks of implementation, the project will measure how many outreach calls each care manager can complete in the time available, how many patients are reached, how long each call takes and how many pended orders are signed within a week. If fewer than half of the monthly target calls can be made, the project will narrow outreach to the two clinics with the largest numbers rather than spreading thinly across six.
Claim 4: The Measure Will Detect the Change
The primary measure, the share of patients with any statin order or pharmacy fill during the last year, is the network's standard measure and is similar in form to national quality measures of statin use in diabetes. But it has a property that matters for detection: because it looks back 12 months, a patient who starts a statin in October moves the October figure, while every patient already counted remains counted for a year. Month-to-month change in a rolling 12-month measure is therefore small and slow even when the intervention works. With 971 patients and about 25 new statin starts a month expected from outreach, the monthly proportion would rise by roughly 2 to 3 points a month, which a run chart can show over six months but which could be hidden by ordinary variation early on. The proposal therefore adds a second measure that responds quickly: new statin starts per month among patients not on a statin at the start of the month. Strength of the original measure for detecting change within six months: moderate; with the added measure: adequate.
What the Arrangement Changed
Arranging the evidence by claim changed the proposal in two ways that a study-by-study summary would have hidden. The weak third link added a feasibility phase with its own measures and a rule for narrowing the rollout. The detection problem in the fourth claim added a second, faster measure. Neither change came from finding a new study; both came from asking whether the studies already found could carry the argument the proposal needed them to carry.
References
Adusumalli, S., Kanter, G. P., Small, D. S., Asch, D. A., Volpp, K. G., Park, S. H., Gitelman, Y., Do, D., Leri, D., Rhodes, C., VanZandbergen, C., Howell, J. T., Epps, M., Cavella, A. M., Wenger, M., Harrington, T. O., Clark, K., Westover, J. E., Snider, C. K., & Patel, M. S. (2023). Effect of nudges to clinicians, patients, or both to increase statin prescribing: A cluster randomized clinical trial. JAMA Cardiology, 8(1), 23-30. https://doi.org/10.1001/jamacardio.2022.4373
American Diabetes Association Professional Practice Committee. (2025). 10. Cardiovascular disease and risk management: Standards of care in diabetes-2025. Diabetes Care, 48(Suppl. 1), S207-S238. https://doi.org/10.2337/dc25-S010
Cholesterol Treatment Trialists' Collaborators. (2008). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. The Lancet, 371(9607), 117-125. https://doi.org/10.1016/S0140-6736(08)60104-X
Weymiller, A. J., Montori, V. M., Jones, L. A., Gafni, A., Guyatt, G. H., Bryant, S. C., Christianson, T. J. H., Mullan, R. J., & Smith, S. A. (2007). Helping patients with type 2 diabetes mellitus make treatment decisions: Statin choice randomized trial. Archives of Internal Medicine, 167(10), 1076-1082. https://doi.org/10.1001/archinte.167.10.1076
DNP 955 Topic 4 instructions, in plain terms
Topic 4 in DNP-955 asks students to present the evidence supporting their project. Strong papers arrange evidence by argument, stating the claims the proposal must establish and placing studies under the claim each supports, rather than summarizing studies one at a time. Students should grade the strength of each link honestly, report where the literature cannot carry a claim, for example evidence from settings unlike the project site, and change the proposal in response, such as adding a feasibility phase. The paper should also check that the chosen measure can detect the expected change, since a proposal can be right about everything else and still fail at measurement.
How the DNP-955 Topic 4 example is put together
The finished example arranges evidence around four claims the proposal must establish: that the problem matters, that the intervention affects it, that it works in settings resembling this one, and that the measure chosen detects the change. Each section gathers whatever bears on that claim. The third link is where it fails, since the supporting studies come from settings with resources this site does not have, and the paper reports that as a finding rather than blurring it. That result changes the proposal, adding a feasibility element the design did not previously contain. The literature is therefore doing work rather than demonstrating that reading occurred. Each claim carries a count of the studies standing behind it rather than a general characterization.
Reading the DNP 955 Topic 4 rubric
Faculty reward evidence placed under the claim it supports. An Excellent paper supports the first claim with the Cholesterol Treatment Trialists' 21 percent reduction among 18,686 people with diabetes. Credit goes to rating the intervention link moderate, from Adusumalli and colleagues' practice-randomized nudge trial, and admitting the setting claim fails. The rubric values checking that the statin order or fill measure, aligned with ADA standards, can detect change. Strong papers use Weymiller and colleagues' decision aid evidence. Top marks go to a feasibility phase added because of the weak link.
Common DNP 955 Topic 4 mistakes, and how to avoid them
Literature arranged by theme rather than by argument is the standard approach and leaves the reader to work out what any of it supports. A second failure is concealing a weak link by writing the section at the same length as the strong ones, which a careful reader detects from the citations. Marks also go for omitting the measurement claim, since a proposal must show its measure can detect a change of the expected size. Reviews that produce no change to the proposal were not used. Transferability asserted without comparing settings skips the question. Claims supported by a single study presented as settled overstate what is known. Sections of equal length regardless of the evidence behind them disguise where the argument is thin.
Get a DNP-955 Topic 4 example written to your instructions
Send the DNP-955 Topic 4 instructions and the rubric your classroom posts, with your proposal and question. We write a custom example to those criteria, arranged around the claims your argument depends on, with strength reported per link and the design changed by what was found, in 24 to 48 hours. The first is free.
More DNP 955 papers and DNP samples
- DNP 955 Topic 1: Practice Problem Revisit
- DNP 955 Topic 2: Project Decision Record
- DNP 955 Topic 3: Clinical Question and Population Tightening
- DNP 955 Topic 5: Framework and Design Defense
- DNP 955 Topic 6: Site Approval DQ Pair
- DNP 955 Topic 7: Measurement and Analysis Plan Draft
- DNP 955 Topic 8: Proposal Assembly and Consistency Pass
- DNP 960A Topic 4: Data Collection Report
- DNP 840 Topic 4: Influence Without Formal Power
- DNP 965A Topic 4: Limitations Statement
- DNP 838A Topic 4: Clinical Placement Plan
DNP 955 Topic 4 questions, answered
What does arranging by argument mean?
Deciding what your proposal has to establish, then gathering evidence per claim. Most proposals depend on four things being true: the problem matters, the intervention affects it, the effect transfers to a setting like yours, and your measure can detect it. A section per claim tells a reader exactly where the argument is strong and where it is thin.
What do I do about a weak link?
Report it and change the proposal. A transferability link supported only by better resourced settings is a genuine risk, and the honest response is to add a feasibility element rather than to write around it. Reviewers find weak links quickly, and finding your own first is the difference between a limitation you managed and one you missed.
Why check the measurement claim?
Because a proposal can be right about everything else and still use a measure too coarse to detect the change it expects. Establishing that this measure has registered differences of similar size in other studies confirms the evaluation can succeed. Skipping it risks a project that works and cannot demonstrate it.
Where can I find a free DNP 955 Topic 4 sample paper?
You can read the whole argument-by-claim review on this page: how the evidence is arranged, four claims with their support, the claim the literature cannot carry and what the arrangement changed. Your own DNP 955 Topic 4 prompt gets a free paper.
What do I do about a weak link in DNP 955 Topic 4?
Report it and change the proposal. The studies came from better-resourced settings, so the project added a feasibility phase with its own measures and a rule for stopping.